Tag: Lupin
Lupin & DKSH sign an exclusive licensing & supply agreement to...
According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved
Lupin & I’rom enter into an exclusive licensing agreement for denosumab...
Following the completion of the clinical trial and receipt of marketing authorization from PMDA in Japan, I’rom will exclusively commercialize the product in Japan
Lupin Diagnostics launches its first regional reference lab in Patna
Company is expanding its diagnostics footprint in East India
Lupin registers net loss of Rs 512 crore in Q4 of...
The company had posted a net profit of Rs 464 crore in the corresponding quarter last fiscal.
Lupin launches its Reference Laboratory in Guwahati
Expanding diagnostics business footprint in North East India
Lupin appoints Diana Amador-Toro as Senior Vice President, Global Compliance
Diana is a senior leader with more than 38 years of field experience in U.S. FDA’s Office of Regulatory Affairs (ORA)
Lupin signs licensing deal with Alvion to market Cardiometabolic drugs in...
By commercializing cardiometabolic drugs in the Southeast Asian region, Lupin will play a significant role in improving the quality of healthcare
Lupin launches its first reference laboratory in East India
Lupin Diagnostics is also setting up laboratories in West Bengal, Assam, Bihar, Jharkhand and Orissa to comprehensively cater to the East India region
Lupin signs distribution agreement with Medis for orphan drug, NaMuscla
Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders in Central and Eastern European territories
Budget 2022: “Focus must be on infrastructure and investment”
Ramesh Swaminathan, Executive Director, Global CFO & Head Corporate Affairs, Lupin Limited lists his expectations from the budget 2022